2026-07-06T07:59:21Z https://icatplus.esrf.fr/oaipmh/request

oai:icatplus.esrf.fr:inv/2341481342 2026-04-13T06:00:43.849Z

4.2 EI 10.15151/ESRF-ES-2341481342 Michele SALMAIN Michele Salmain 0000-0003-3039-5659 Olivier PROUX Olivier Proux 0000-0003-0385-1815 BENOIT BERTRAND Benoit Bertrand 0000-0003-0542-4454 Annabelle BONINO Annabelle Bonino Michele SALMAIN Michele Salmain 0000-0003-3039-5659 Jean Louis HAZEMANN Jean-Louis Hazemann 0000-0002-3717-2151 Annabelle BONINO Annabelle Bonino BENOIT BERTRAND Benoit Bertrand 0000-0003-0542-4454 Tom LACOMA Tom Lacoma 0009-0007-0501-3213 Tom LACOMA Tom Lacoma 0009-0007-0501-3213 Example Institute 2029 Data from large facility measurement 2026-04-08T06:30:00Z/2026-04-13T06:00:00Z 2026-04-13T06:00:00Z I CC-BY-4.0 Linear, two-coordinate gold(I) complexes comprising an N-heterocyclic carbene (NHC) ligand and various other coligands have been found to display anticancer properties related to the nature of the ancillary ligand. Since gold(I) compounds are known to act as prodrugs, undergoing activation via ligand(s) exchange, uncovering the still unknown biotransformation pathways sustained by NHC-gold(I) complexes will provide complementary data regarding their mechanism of action. Following previous experiments at the BM16 beamline (exps. LS-3235 and LS-3432), we successfully determined the speciation of biphenyl gold(III) complexes in cancer cells from cryo-X-ray absorption spectroscopy (XAS) measurements. We now apply for beamtime at BM16 in order to investigate the intracellular speciation of five different NHC-gold(I) compounds to try and draw a relationship between their structure, biotransformation and cytotoxic activity.